25 studies were found.

1.		Recruiting	3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors Condition: unspecified adult solid tumor, protocol specific
2.		Completed	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction Conditions: adult non-Hodgkin's lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm
3.		No longer recruiting	Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer Conditions: stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
4.		Recruiting	Combination Chemotherapy in Treating Patients With Advanced Cancer Condition: unspecified adult solid tumor, protocol specific
5.		Recruiting	Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
6.		No longer recruiting	Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer Conditions: Drug Toxicity; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
7.		Recruiting	Doxercalciferol Before Surgery in Treating Localized Prostate Cancer Conditions: adenocarcinoma of the prostate; stage I prostate cancer; stage II prostate cancer
8.		Recruiting	Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Conditions: Chronic Myelomonocytic Leukemia; previously treated myelodysplastic syndromes; secondary myelodysplastic syndromes; de novo myelodysplastic syndromes; ...
9.		No longer recruiting	Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Conditions: prevention of skin cancer; basal cell carcinoma of the skin; squamous cell carcinoma of the skin
10.		Completed	Endostatin in Treating Patients With Advanced Refractory Solid Tumors Condition: unspecified adult solid tumor, protocol specific
11.		No longer recruiting	Flavopiridol in Treating Patients With Recurrent Prostate Cancer Conditions: stage IV prostate cancer; adenocarcinoma of the prostate
12.		No longer recruiting	Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases Condition: skin metastases
13.		Recruiting	Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors Condition: unspecified adult solid tumor, protocol specific
14.		No longer recruiting	Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma Conditions: Stage IV Melanoma; stage III melanoma; Recurrent Melanoma
15.		No longer recruiting	Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
16.		No longer recruiting	Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Condition: Cancer
17.		No longer recruiting	Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer Condition: recurrent non-small cell lung cancer
18.		Completed	Penclomedine in Treating Patients With Solid Tumors or Lymphoma Condition: Cancer
19.		No longer recruiting	Perifosine in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
20.		Completed	Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer
21.		Completed	Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Condition: recurrent prostate cancer
22.		No longer recruiting	PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors Condition: unspecified adult solid tumor, protocol specific
23.		Completed	Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma Conditions: Lung Cancer; Leukemia; Esophageal Cancer; Lymphoma
24.		No longer recruiting	Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma Conditions: Stage IV Melanoma; stage III melanoma; Recurrent Melanoma
25.		No longer recruiting	Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma Condition: recurrent adult soft tissue sarcoma